NCT07654296
Assessing Suzetrigine for Pain Reduction Following Ureteroscopic Surgery
Not Yet Recruiting
PHASE3Ages 21–80InterventionalTreatmentBrigham and Women's HospitalInvestigator-initiated
~100 participants
Updated 2026-06-17 on ClinicalTrials.gov
What's tested:multimodal analgesia regimen without suzetrigineSuzetrigine
At a glance
Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Post-discharge opioid consumption (MME)
Measured over 1-2 weeks
Conditions
Where it's being run
2 sites across 1 statesMassachusetts2
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Patients undergoing ureteroscopy between ages 21 to 80 at BWFH (Brigham \& Women's Faulkner Hospital) by one of the department's high volume endoscopic surgeons. Patient who are or not pre-stented prior to surgery will be included (these will be assessed via stratification within a secondary analysis).
Patients able to consent for their own medical care (i.e. consent able to be obtained directly from patient and does not require a healthcare proxy or guardian)
Exclusion
Regular opioid use prior to surgery or significant substance abuse concerns.
Inability of patient to provide their own consent (i.e. lack capacity).
What this trial measures
- Post-discharge opioid consumption (MME)1-2 weeks
assessed at post-operative visit